analyze & realize GmbH
Berlin, State of Berlin, D-13467, Germany
NCT Number: NCT02930681
Glucosanol had previously been proven to be effective in aiding weight loss and weight loss maintenance. Studies have also shown that Glucosanol (also known as Phaseolamin), was effective in aiding weight loss and also has evidence on reducing post-prandial glucose levels. This study is to enrich the existing evidence on dose-dependent post-prandial glucose effects of Glucosanol
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Berlin, State of Berlin, D-13467, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 120 mins
Change defined as incremental AUC0 - AUC120min in mmol/(L*min)
InQpharm Group
Industry
Double-blind, Randomised, Placebo-controlled, 3-way Cross-over Study to Evaluate the Benefit of Two Glucosanol™ Dosages to Reduce Post-prandial Glucose Levels in Overweight Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04730882
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06241976
Glucose Metabolism Disorders, Hyperglycemia
London, United Kingdom
View Trial DetailsNCT05528874
Appetitive Behavior, Behavior
Novara, Italy
View Trial DetailsNCT04163874
Autoimmune Diseases, Diabetes Mellitus
Montreal, Quebec, Canada
View Trial Details